Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMYT Amryt Pharma	$14.70 +0.1%	$14.64	$6.41 ▼ $14.77	$940.21M	0.84	757,360 shs	2.39 million shs
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	$22.94 +0.1%	$23.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
CNBTF Cannara Biotech	$0.64	$0.69	$0.08 ▼ $0.20	N/A	N/A	33,127 shs	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	$22.85 -0.2%	$24.60	$22.33 ▼ $26.88	N/A	N/A	1,044 shs	300 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMYT Amryt Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	+0.04%	-0.22%	-0.74%	0.00%	+3.95%
CNBTF Cannara Biotech	0.00%	0.00%	-8.14%	+4.55%	+16.59%
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	0.00%	+0.09%	+0.75%	+1.73%	+1.55%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNBTF Cannara Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMYT Amryt Pharma	N/A	N/A	N/A	N/A
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	0.00	N/A	N/A	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	0.00	N/A	N/A	N/A
CNBTF Cannara Biotech	N/A	N/A	N/A	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMYT Amryt Pharma	$222.54M	4.22	$0.98 per share	14.98	$5.58 per share	2.63
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	N/A	N/A	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	N/A	N/A	N/A
CNBTF Cannara Biotech	N/A	N/A	N/A	N/A	N/A	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMYT Amryt Pharma	$1M	-$0.06	N/A	735.00	N/A	-8.19%	1.70%	0.75%	N/A
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CNBTF Cannara Biotech	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	N/A	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	N/A	N/A
CNBTF Cannara Biotech	N/A	N/A	N/A	N/A	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	$0.74	3.24%	N/A	N/A	N/A

Latest PYT, AMYT, BGFPX, BGFVX, and CNBTF Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/14/2024	PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	quarterly	$0.4147	7%	2/14/2024	2/14/2024	2/15/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMYT Amryt Pharma	0.64	1.57	0.94
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A
CNBTF Cannara Biotech	N/A	N/A	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
AMYT Amryt Pharma	71.31%
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A
CNBTF Cannara Biotech	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	N/A

Insider Ownership

Company	Insider Ownership
AMYT Amryt Pharma	5.66%
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A
CNBTF Cannara Biotech	N/A
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AMYT Amryt Pharma	2,020	63.96 million	60.34 million	Not Optionable
BGFPX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	Not Optionable
BGFVX Blackstone / GSO Floating Rate Enhanced Income Fund	N/A	N/A	N/A	Not Optionable
CNBTF Cannara Biotech	13	N/A	N/A	Not Optionable
PYT PPLUS Trust Series GSC-2 GSC 2 CT FL RT	147,000	N/A	N/A	Not Optionable

PYT, AMYT, BGFPX, BGFVX, and CNBTF Headlines

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Company Descriptions

Amryt Pharma

NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial